EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Use of Proton Pump Inhibitors Among Patients With Alcohol‐Related Cirrhosis—A Danish Nationwide Cohort Study

Marine Sølling Ramsing iD, Morten Daniel Jensen iD, Peter Jepsen iD

Liver International · 2025

DOI: 10.1111/liv.70061 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Liver International, 2025. Verfasst von Marine Sølling Ramsing und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Liver Cirrhosis, Alcoholic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Use of proton pump inhibitors (PPIs) may have adverse effects in patients with alcohol‐related cirrhosis (ALD cirrhosis), but PPIs continue to be used by many patients.

Aims

We aimed to describe the prevalence and incidence of PPI use from filled prescriptions among patients with ALD cirrhosis and to identify predictors of PPI initiation after ALD cirrhosis diagnosis.

Methods

We used Danish nationwide healthcare registries to investigate PPI use among patients diagnosed with ALD cirrhosis from 1997 to 2022. We used multivariable Cox regression to identify predictors of PPI initiation.

Results

We identified 41 263 patients diagnosed with ALD cirrhosis in 1997–2022. In this cohort, the prevalence of PPI use rose to 40% in 2016 and plateaued at this level through 2022. Considering time since diagnosis, 26% were using PPI at the diagnosis of ALD cirrhosis, and the prevalence peaked at 38% 3 months later. Among PPI users, 79% used more than 30 defined daily doses per year on average during the follow‐up. Patients older than 50 years were more likely than younger patients to initiate PPI treatment.

Conclusion

The use of PPIs continues to be prevalent among patients with ALD cirrhosis, with 40% of all patients using PPIs in 2022. Within the first 3 months after diagnosis, 38% of all patients were using PPIs. Our results provide essential background information for future RCTs on the risks and benefits of prescribing or deprescribing PPIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump InhibitorsLiver Cirrhosis, AlcoholicHumansDenmarkFemaleMaleMiddle AgedAgedRegistriesAdultCohort StudiesProportional Hazards ModelsPrevalence

Stichwörter der Autor:innen

alcohol‐related cirrhosisepidemiologynationwide cohort‐studypredictorsprevalenceproton pump inhibitors

Substanzen

Proton Pump Inhibitors

Autor:innen und Institutionen

  • Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Marine Sølling Ramsing, Morten Daniel Jensen, Peter Jepsen

Förderung

  • Novo Nordisk Fonden

Zitieren

APA

Ramsing, M. S., Jensen, M. D., & Jepsen, P. (2025). Use of Proton Pump Inhibitors Among Patients With Alcohol‐Related Cirrhosis—A Danish Nationwide Cohort Study. Liver International. https://doi.org/10.1111/liv.70061

Vancouver

Ramsing MS, Jensen MD, Jepsen P. Use of Proton Pump Inhibitors Among Patients With Alcohol‐Related Cirrhosis—A Danish Nationwide Cohort Study. Liver International. 2025. doi:10.1111/liv.70061

BibTeX
@article{Ramsing2025,
  author = {Ramsing, Marine Sølling and Jensen, Morten Daniel and Jepsen, Peter},
  title = {Use of Proton Pump Inhibitors Among Patients With Alcohol‐Related Cirrhosis—A Danish Nationwide Cohort Study},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70061}
}
Kostenlos starten →